IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.
A July 2026 comparison of Claude Science, GPT-Rosalind, and Isomorphic Labs covering pricing, access models, published benchmarks, named enterprise adoption, and which platform fits which life-sciences use case.
A 2026 analyst report on Chai Discovery's $400M Series C at a $3.8B valuation, covering Chai-3 benchmarks, Lilly, Pfizer, Novartis, and argenx deals, and AI drug discovery megaround trends.
An in-depth analysis of Isomorphic Labs' $2.1B Series B funding. Examine the IsoDDE AI drug design engine, AlphaFold's role, and biotech industry impacts.
Examine how Isomorphic Labs uses AlphaFold AI to advance its first computationally designed oncology and immunology therapeutics into clinical trials.
How AI leaders like Amodei, Hassabis, and Huang are accelerating drug discovery, genomics, and life science breakthroughs—compressing decades into years. Updated January 2026 with AlphaFold 3, Claude for Life Sciences, NVIDIA Evo 2, and $3B+ pharma partnerships.
© 2026 IntuitionLabs. All rights reserved.
